바이오인

All together now :

 Improving cross-sector collaboration in the UK biomedical industry

Executive summary

A strong history in pharmaceuticals and chemicals, combined with world-leading university research, has created a significant competitive advantage for the UK biomedical sciences industry. This industry is important to the UK economy, accounting for 9 per cent of exports and 28 per cent of business R&D spending.1 It is an industry where the UK is objectively one of the world leaders, but our role is not secure. As Pfizer announces the closure of its UK R&D facility, the only one outside of the US, it is clear that our historic advantages will not be enough to sustain the UK’s position in the future. As pharmaceutical companies change their R&D strategies to a new, more outsourced model, and other countries improve their scientific infrastructure, we need to change to keep up.

However, there is an opportunity to raise our game by building better connections between the assets we already have.

....(계속)

☞ 자세한 내용은 첨부파일을 참고하시기 바랍니다.